Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrogen peroxide topical - Aclaris Therapeutics

Drug Profile

Hydrogen peroxide topical - Aclaris Therapeutics

Alternative Names: A-101 - Aclaris; A-101 45%; ESKATA; ESKERIELE; HP-40; HP-45; Oxydol; V-101 - Aclaris

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aclaris Therapeutics
  • Developer Aclaris Therapeutics; Cipher Pharmaceuticals
  • Class Antibacterials; Antiseptics; Disinfectants; Peroxides; Skin disorder therapies
  • Mechanism of Action Antioxidants; Free radical stimulants; Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Seborrhoeic keratosis; Warts

Highest Development Phases

  • Preregistration Seborrhoeic keratosis
  • Phase III Warts

Most Recent Events

  • 24 Oct 2019 Efficacy and adverse events data from the phase III THWART-1 trial released by Aclaris Therapeutics
  • 16 Sep 2019 Efficacy and adverse events data from the phase III THWART-2 released by Aclaris Therapeutics
  • 06 Sep 2019 Aclaris Therapeutics completes the phase III THWART-1 trial for Wart in USA (Topical) (NCT03687372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top